NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine

Commercially releasable ketamine supply is on hand, but FDA approval remains pending.

Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) completed manufacturing process validation for preservative-free ketamine, producing three commercial lots ahead of its regulatory review goal date.

The lots were produced under commercial conditions in compliance with FDA Good Manufacturing Practices. Process validation is the final manufacturing step required to demonstrate that compliance. Two-year, real-time room-temperature stability testing showed no deterioration in purity, potency, or sterility without preservatives. NRx believes these data support a labeled shelf life of three years or longer.

Commercially releasable supply is on hand, but release remains subject to FDA approval of the Abbreviated New Drug Application (ANDA). The regulatory review goal date is November 10, 2026. NRx said it is positioned to supply the drug-shortage product immediately upon approval, with Nephron Pharmaceuticals as its manufacturing partner.

4 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointThree commercial lots completed process validation in compliance with FDA Good Manufacturing Practices.
• Moderate pointTwo-year room-temperature stability data showed no deterioration in purity, potency, or sterility without preservatives.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Commercially releasable supply is on hand; NRx says it can supply immediately upon approval.
• Minor point. Forward-looking: it has not happened yet and may not happen.NRx believes stability data support a labeled shelf life of three years or longer.

Negative

• Moderate pointFDA approval of the ANDA remains pending, with a November 10, 2026 regulatory review goal date.

Key Figures

Commercial process-validation lots: 3 commercial lots Room-temperature stability data: 2 years GDUFA goal date: November 10, 2026

Commercial process-validation lots

3 commercial lots

Preservative-free ketamine; manufactured in compliance with process-validation requirements

Room-temperature stability data

2 years

No deterioration in purity, potency, or sterility reported

GDUFA goal date

November 10, 2026

Preservative-free ketamine ANDA

Historical Context

1 past event · Latest: Oct 15

1 event

1. Oct 15

   FDA labeling review

   24h Move

   +4.6%

   FDA requested minor label changes while manufacturing process-validation runs remained underway.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gdufa, good manufacturing practices, gmp, process validation

4 terms

gdufa regulatory

"November 10, 2026 GDUFA goal date"

GDUFA is a U.S. regulatory program that charges fees to makers of generic drugs to fund and speed up the government review and inspection process for generic medicines and manufacturing sites. For investors, it matters because the program influences how fast generics reach the market, the cost burden on manufacturers, and the ability of companies to scale production—similar to paying for faster processing at a government office that can affect a business’s timing and margins.

good manufacturing practices regulatory

"required under FDA “Good Manufacturing Practices” (GMP)"

Good manufacturing practices are a set of required processes, controls and documentation that ensure products are made consistently, safely and to quality standards — like following a precise recipe in a clean kitchen so every batch turns out the same. For investors, compliance matters because it affects a maker’s ability to get regulatory approval, avoid costly recalls or production stoppages, and maintain customer and market trust, all of which influence revenue and risk.

gmp regulatory

"FDA “Good Manufacturing Practices” (GMP)"

Good Manufacturing Practice (GMP) is a set of regulatory standards and procedures that ensure products—especially medicines, medical devices, and related goods—are consistently made to meet safety, quality, and purity requirements. For investors, GMP compliance is like a factory’s hygiene and checklist system: it reduces the risk of product recalls, regulatory fines, and production stoppages, supports market access, and signals more reliable, lower-risk operations that can protect revenue and reputation.

process validation technical

"three Process Validation lots of preservative free Ketamine"

Process validation is the documented proof that a manufacturing or production method reliably and consistently makes a product that meets required quality and safety standards. Think of it like proving a recipe always produces the same good cake: once validated, the process reduces the chance of defects, regulatory problems, production delays and costly recalls, so investors view it as a sign of lower operational and compliance risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing Practices” (GMP).
• NRx has additionally received two year stability data consistent with projected room-temperature stability to three years and beyond with no need for toxic preservatives.
• Commercially-releasable drug supply is now on hand pending ANDA approval for this drug-shortage product.
  

WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, today announces completion of three Process Validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 GDUFA (Generic Drug User Fee Amendments) Goal Date. Process Validation¹ is the final step in the drug manufacturing process required to demonstrate compliance with FDA Good Manufacturing Practices (GMP).

In related developments, NRx has now completed analysis of two-year room temperature real-time stability data on preservative-free ketamine demonstrating no deterioration in purity, potency, or sterility without the need for toxic preservatives. The Company believes that these data will be consistent with a labeled shelf life of three years or longer.

“Completing Process Validation and reaching two years of room-temperature stability puts NRx in position to supply this drug-shortage product the moment the FDA approves our ANDA,” said Jonathan Javitt, MD, MPH, the Company’s Chairman and CEO. “We thank our partners at Nephron Pharmaceuticals in West Columbia, South Carolina, for helping us show that sterile, preservative-free injectables can be made in America, and we look forward to supplying American hospitals and clinics.”

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com

---

¹ https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What manufacturing milestone did NRx Pharmaceuticals complete for preservative-free ketamine?

NRx completed three process validation lots of preservative-free ketamine under commercial conditions in compliance with FDA Good Manufacturing Practices. Process validation is the final manufacturing step required to demonstrate that compliance.

What did NRXP's two-year preservative-free ketamine stability testing show?

Two-year, real-time testing at room temperature showed no deterioration in purity, potency, or sterility without preservatives. NRx believes the data are consistent with a labeled shelf life of three years or longer; that longer shelf life remains the company's expectation.